Nektar Therapeutics Files 8-K

Ticker: NKTR · Form: 8-K · Filed: Dec 16, 2025 · CIK: 906709

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

TL;DR

Nektar filed an 8-K on 12/16/25, check for material updates.

AI Summary

Nektar Therapeutics filed an 8-K on December 16, 2025, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. Specific details regarding the nature of these events or any associated financial figures were not immediately available in the provided text.

Why It Matters

This 8-K filing indicates that Nektar Therapeutics is disclosing material information to the public, which could impact investor decisions.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not inherently signal significant risk without further details on the disclosed events.

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The provided text of the 8-K filing does not specify the exact nature of the Regulation FD disclosures.

Are there any significant financial updates or exhibits included in this filing?

The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content is not detailed in the provided text.

What is the primary business of Nektar Therapeutics?

Nektar Therapeutics is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

When was Nektar Therapeutics incorporated?

Nektar Therapeutics was incorporated in Delaware.

What was the previous name of Nektar Therapeutics?

Nektar Therapeutics was formerly known as INHALE THERAPEUTIC SYSTEMS INC, with a name change date of July 23, 1998, and prior to that, INHALE THERAPEUTIC SYSTEMS, with a name change date of March 3, 1994.

Filing Stats: 1,841 words · 7 min read · ~6 pages · Grade level 12.3 · Accepted 2025-12-16 08:00:21

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's rezpegaldesleukin program in alopecia areata, including plans to submit the REZOLVE-AA results from the 36-week induction treatment period for presentation at a medical conference in 2026, and timing for the 16-week extension data from the Phase 2b REZOLVE-AA (alopecia areata) clinical trial. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan," "on track," or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this Current Report on Form 8-K are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: (i) the Company's statements regarding the therapeutic potential of rezpegaldesleukin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Nektar Therapeutics on December 16, 2025, furnished herewith 99.2 Nektar Therapeutics Presentation, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: December 16, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing